Spots Global Cancer Trial Database for EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

Official Title: EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

Study ID: NCT04141462

Conditions

Cancer

Genetic Predisposition

Interventions

blood sample

Study Description

Brief Summary: 5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.

Detailed Description: The main objective of this study is to evaluate the interest of the SHD-E approaches after a negative result of the analysis called " gene panel " tested in routine in order to identify a genetic factor of predisposition to the cancer.